

C² PHARMA'S UPCOMING LAUNCH OF NEW API

OXYBUPROCAINE HYDROCHLORIDE

Cork, Ireland, March 5th 2024 – [C² PHARMA](#), the global leader in ophthalmic and niche active pharmaceutical ingredients (APIs), is excited to announce the upcoming launch of their new API, Oxybuprocaine HCL, an API that will be manufactured by our manufacturing partner [Laurus Labs](#). The addition of this API will extend our range of high-quality Ophthalmic APIs and strengthen our commitment to meeting the market's evolving needs.

Oxybuprocaine (also known as Benoxinate), is a local topical anesthetic used especially in ophthalmology and otolaryngology for short term medical procedures. We are completing the validation process, by April 2024, and upon completion, GMP samples will be available to our customers worldwide for evaluation and testing.

We expect to submit a Certificate of Suitability (CEP) by May 2024, a US-Drug Master File (US-DMF) by August 2024, and a Certificate of Acceptance of Drugs and Food (CADIFA) in Q4 of 2024.

“At C² PHARMA we understand the importance of being able to deliver ophthalmic APIs meeting the highest quality standards and the best cost-to-quality and cost-to-reliability in the industry. We are committed to providing our customers with the most dependable service level for ophthalmic APIs.” states Andrew Badrot, CEO of C² PHARMA. “We will further be expanding our range of high quality Ophthalmic-APIs throughout 2024, with our next release being Naphazoline Hydrochloride.”

The company will be attending DCAT from March 18th - 21st in New York City. To schedule a meeting or to receive further information regarding Oxybuprocaine HCL and other products in our [portfolio](#), please contact info@c2pharma.com.

About C² PHARMA

C² PHARMA is an Irish pharmaceutical group established in 2014. It manufactures and distributes active pharmaceutical ingredients (APIs) and complex chemical compounds obtained from synthetic and natural origins. We reach more than 200 pharmaceutical companies across the world. Customized GDP cold-chain logistics solutions are offered through our specialized affiliate, [Logistics4Pharma](#) (Frankfurt, Germany)..